Showing 8281-8290 of 8907 results for "".
- Ferndale Healthcare Launches Vegetarian Formula of Heliocarehttps://practicaldermatology.com/news/ferndale-healthcare-launches-vegetarian-formula-of-heliocare/2458868/Ferndale Healthcare® has introduced to its existing Heliocare® line a new vegetarian formula, free of gluten and artificial dyes. The new Heliocare® Ultra Dietary Supplement contains a powerful blend of antioxidants, including Fernblock®
- New Study Shows Cryolipolysis Reduces Enlarged Male Breastshttps://practicaldermatology.com/news/new-study-shows-cyrolipolyis-reduces-enlarged-male-breasts/2458871/Fat-freezing provides a safe and effective non-surgical alternative for men seeking breast reduction procedures, according to a new scientific analysis. Of the men who underwent fat-freezing treatments as part of the study, 95 percent noted an improved appearance and 89 percent cited less embarra
- The National Eczema Association Names Amy Fauver New VP For Advocacy & Accesshttps://practicaldermatology.com/news/the-national-eczema-association-names-amy-fauver-new-vp-for-advocacy-access/2458872/The National Eczema Association (NEA) named Amy Fauver as Vice President for Advocacy and Access. The NEA says in this new position, Ms. Fauver will build its advocacy capacity and better leverage the voices of the eczema community, enhancing NEA’s ability to create meaningful changes in ec
- Cynosure to Host Investor Event to Introduce SculpSurehttps://practicaldermatology.com/news/cynosure-to-host-investor-event-to-introduce-sculpsure/2458877/Cynosure, Inc. will host an investor event in New York City on Tuesday, September 15 to introduce SculpSure™, the only FDA-cleared hyperthermic laser treatment for non-invasive fat reduction. The Company will provide a live webcast of the event presentations from approximately 10:00 a.m. to
- FDA Approves Updated Label for Allergan's Teflaro for Treatment of ABSSSIhttps://practicaldermatology.com/news/fda-approves-updated-label-for-allergans-teflaro-for-treatment-of-absssi/2458880/The FDA approved Allergan’s supplemental new drug application (sNDA) to update the label for Teflaro® (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
- AAD Releases Second Set of Choosing Wisely Recommendationshttps://practicaldermatology.com/news/aad-releases-second-set-of-choosing-wisely-recommendations/2458884/The American Academy of Dermatology (AAD) released its second set of recommendations regarding dermatologic tests and treatments that are not always necessary. These recommendations were developed as part of the
- Novartis Drug Odomzo Gains EU Approval for Locally Advanced Basal Cell Carcinomahttps://practicaldermatology.com/news/novartis-drug-odomzo-gains-eu-approval-for-locally-advanced-basal-cell-carcinoma/2458887/Novartis has announced the European Commission approval of Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to cura
- DermTube Kicks Off Video Coverage of SAAD in New Yorkhttps://practicaldermatology.com/news/dermtube-kicks-off-video-coverage-of-saad-in-new-york/2458889/With the American Academy of Dermatology meeting currently underway in New York, Practical Dermatology® magazine and DermTube have begun their joint video coverage of the event, with video interview with key opinion leaders. Su
- Court Rules in Favor of Amarin Corp. in "Off-label" Disputehttps://practicaldermatology.com/news/court-rules-in-favor-of-amarin-corp-in-off-label-dispute/2458897/Amarin Corporation plc (NASDAQ: AMRN) today announced a United States District Court has ruled that Amarin may promote to healthcare professionals certain uses of Amarin'slead product, Vascepa®(icosapent ethyl) c
- Almirall Completes Investment in Suneva Medicalhttps://practicaldermatology.com/news/almirall-completes-investment-in-suneva-medical/2458900/Barcelona-based Almirall, a global pharmaceutical company, has closed a $15 million in Series C equity investment in Suneva Medical, Inc., marketer of Bellafill®. This product i